Search research articles
Contact Us
Filters
Showing results (1-10 of 44) with videos related to
Page
of 5
Sort By:
ACS Medicinal Chemistry Letters
|
June 6, 2014
Cracking the code: the promise of epigenetics
Dashyant Dhanak
Nature
|
October 25, 2013
Chromatin proteins and modifications as drug targets
Kristian Helin, Dashyant Dhanak
Biochemical and Biophysical Research Communications
|
July 13, 2014
Development and classes of epigenetic drugs for cancer
Dashyant Dhanak, Paul Jackson
Trends in Pharmacological Sciences
|
April 23, 2004
From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function
Stephen A Douglas, Dashyant Dhanak, Douglas G Johns
Cell Chemical Biology
|
September 23, 2017
Small-Molecule Targets in Immuno-Oncology
Dashyant Dhanak, James P Edwards, Ancho Nguyen, et al.
Journal of Molecular and Cellular Cardiology
|
June 27, 2006
Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation
Nicolas Bousette, Fu Hu, Eliot H Ohlstein, et al.
Journal of Molecular and Cellular Cardiology
|
September 21, 2005
A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker
Ewa Rakowski, Ghada S Hassan, Dashyant Dhanak, et al.
Peptides
|
August 22, 2006
Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease
Nicolas Bousette, Julia Pottinger, Wisam Ramli, et al.
British Journal of Pharmacology
|
October 3, 2002
Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist
David J Behm, Christopher L Herold, Eliot H Ohlstein, et al.
Biochemistry
|
December 1, 2004
Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition
Lusong Luo, Jeffrey D Carson, Dashyant Dhanak, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 44) with videos related to
Sort By:
Page
of 5
ACS Medicinal Chemistry Letters
|
June 6, 2014
Cracking the code: the promise of epigenetics
Dashyant Dhanak
Nature
|
October 25, 2013
Chromatin proteins and modifications as drug targets
Kristian Helin, Dashyant Dhanak
Biochemical and Biophysical Research Communications
|
July 13, 2014
Development and classes of epigenetic drugs for cancer
Dashyant Dhanak, Paul Jackson
Trends in Pharmacological Sciences
|
April 23, 2004
From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function
Stephen A Douglas, Dashyant Dhanak, Douglas G Johns
Cell Chemical Biology
|
September 23, 2017
Small-Molecule Targets in Immuno-Oncology
Dashyant Dhanak, James P Edwards, Ancho Nguyen, et al.
Journal of Molecular and Cellular Cardiology
|
June 27, 2006
Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation
Nicolas Bousette, Fu Hu, Eliot H Ohlstein, et al.
Journal of Molecular and Cellular Cardiology
|
September 21, 2005
A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker
Ewa Rakowski, Ghada S Hassan, Dashyant Dhanak, et al.
Peptides
|
August 22, 2006
Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease
Nicolas Bousette, Julia Pottinger, Wisam Ramli, et al.
British Journal of Pharmacology
|
October 3, 2002
Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist
David J Behm, Christopher L Herold, Eliot H Ohlstein, et al.
Biochemistry
|
December 1, 2004
Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition
Lusong Luo, Jeffrey D Carson, Dashyant Dhanak, et al.
Page
of 5